Author:
Pan Mingzhu,Liu Yali,Sang Tian,Xie Jiajun,Lin Huishu,Wei Jianpeng,Shao Shuai,Zheng Yanying,Zhang Juan
Funder
the National Natural Science Foundation
the National College Students Innovation and Entrepreneurship Training Program
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference50 articles.
1. Barenholz Y (2012) Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117–134
2. He H, Liu L, Morin E, Liu M (2019) Schwendeman AJAocr. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures 52(9):2445–2461
3. Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updates 29:90–106
4. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904
5. Füredi A, Szebényi K, Tóth S, Cserepes M, Hámori L, Nagy V et al (2017) Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J Control Release 261:287–296
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献